LPC
JANX icon

Lion Point Capital’s Janux Therapeutics JANX Stock Holding History

Lion Point Capital’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$292K Hold
19,000
– – 1.4% 26
2026
Q1 		$264K Hold
19,000
– – 1.58% 27
2025
Q4 		$262K Buy
+19,000
New +$447K 1.36% 31

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Lion Point Capital's JANX Position: Q2 2026 in Review

Lion Point Capital held its Janux Therapeutics (JANX) position steady in Q2 2026 at 19,000 shares worth $292K. The position accounts for 1.4% of the portfolio, ranked #26.

Lion Point Capital first reported a position in JANX in Q4 2025 and has held it in 3 quarters since. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Lion Point Capital held 19,000 shares of Janux Therapeutics worth $292K as of Q2 2026.
  • Lion Point Capital left its Janux Therapeutics share count unchanged in Q2 2026.
  • Janux Therapeutics made up 1.4% of Lion Point Capital's portfolio in Q2 2026, its #26 holding.
  • Lion Point Capital first reported a position in Janux Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Lion Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.